NEW YORK, April 13: A recent study conducted by the Centers for Disease Control and Prevention (CDC) has concluded that mRNA vaccines for the COVID-19 virus are not associated with cardiac death in younger adults, alleviating concerns raised by reported cases of myocarditis.

The study, based on Oregon death certificate data spanning from June 1, 2021, to December 31, 2022, focused on individuals aged 16 to 30 who succumbed to heart-related conditions. This investigation was prompted by reports of myocarditis cases following COVID-19 vaccination, documented in the Vaccine Adverse Event Reporting System.

Among the 40 individuals in the study who had received a COVID-19 vaccine dose and subsequently passed away, the CDC found that only three died within 100 days of vaccination. Further analysis revealed that two of these deaths were attributed to pre-existing health conditions, while the cause of death for the third individual remained undetermined.

"The data do not support an association of COVID-19 vaccination with sudden cardiac death among previously healthy young persons," stated the CDC.

While the risk of myocarditis-related mortality was marginally elevated for younger individuals in 2021, the CDC's findings underscored that it remained an infrequent cause of death within this demographic.

In the same time frame, 30 Oregon residents within the specified age group succumbed to COVID-19, with only three of the deceased having received any form of COVID-19 vaccine.

Acknowledging the limitations of the study, the CDC highlighted that vaccine-related cardiac deaths beyond the 100-day mark could not be conclusively excluded. However, the agency referenced published data indicating that adverse effects associated with vaccinations typically manifest within 42 days of administration.

Additionally, the study emphasized that the relatively small sample size reduced the likelihood of detecting rare events such as sudden cardiac death among the studied population.

Despite these findings, the CDC continues to advocate for COVID-19 vaccination among all individuals aged 6 months and older, emphasizing its role in preventing infection, complications, and fatalities associated with the virus.